LabGenomics Signs MOU with Humanscape to Target Overseas Markets

[Asia Economy Reporter Jang Hyowon] LabGenomics, a molecular diagnostics specialist company (CEO Jin Seunghyun), announced on the 20th that it has signed a strategic business agreement (MOU) with Humanscape, a digital healthcare specialist company (CEO Jang Minhoo), to develop the DTC genetic testing business in the Southeast Asian and US markets.

This agreement was established to jointly target overseas markets by combining LabGenomics' DTC service capabilities, including various prenatal and postnatal genetic tests for mothers and babies, with Humanscape's platform service capabilities, which operates Mamitok, a pregnancy/childcare platform with 600,000 cumulative subscribers. In particular, Humanscape's flagship service Mamitok offers various content such as fetal management through ultrasound video recording services during pregnancy and infant growth record solutions after childbirth, making it easier to secure potential customers.

Both companies had been conducting their respective overseas local businesses starting with Singapore and Vietnam, but going forward, they plan to expand the market by integrating their services into a single platform with more diverse and useful services. Recently, they have also planned to establish joint facilities for localization of testing services in the Indonesian and Vietnamese markets, which have relatively high birth rates, and have begun preparations for these services with major local national hospitals in advance.

A LabGenomics official stated, “It is true that there were difficulties in discovering new services and distribution channels while operating our flagship prenatal/postnatal testing services overseas,” adding, “LabGenomics expects to achieve excellent results early in overseas markets through cooperation with Humanscape.”

This content was produced with the assistance of AI translation services.